Coffee and liver health

Journal of Clinical Gastroenterology

Volumn 48, Issue , 2014, Pages S87-S90

  Morisco, Filomena ^a   Lembo, Vincenzo ^a   Mazzone, Giovanna ^a   Camera, Silvia ^a   Caporaso, Nicola ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cirrhosis; Coffee; Hepatocellular carcinoma; NAFLD

Indexed keywords

LIVER ENZYME; COFFEE;

CANCER THERAPY; COFFEE; CONFERENCE PAPER; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; NONHUMAN; VIRUS HEPATITIS; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; ENZYMOLOGY; LIVER; LIVER DISEASES; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROTECTION; RISK FACTOR; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; COFFEE; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTECTIVE FACTORS; RISK FACTORS;

EID: 84916604464     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000240     Document Type: Conference Paper

References (54)

1. Larsson SC. Coffee, tea, and cocoa and risk of stroke. Stroke. 2014;45:309-314.
2. Spiller MA. The chemical components of coffee. Prog Clin Biol Res. 1984;158:91-147.
3. Gómez-Ruiz JA, Leake DS, Ames JM. In vitro antioxidant activity of coffee compounds and their metabolites. J Agric Food Chem. 2007;55:6962-6969.
4. Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr. 2006;46:101-123.
5. Freedman ND, Park Y, Abnet CC, et al. Association of coffee drinking with total and cause-specific mortality. N Engl J Med. 2012;366:1891-1904, 17.
6. Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Curr Opin Lipidol. 2007;18:13-19.
7. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease. Geriatr Gerontol Int. 2014;14:430-439.
8. Greenland S. A meta-analysis of coffee, myocardial infarction, and coronary death. Epidemiology. 1993;4:366-374.
9. Wu JN, Ho SC, Zhou C, et al. Coffee consumption and risk of coronary heart diseases: a meta-analysis of 21 prospective cohort studies. Int J Cardiol. 2009;137:216-225.
10. Sugiyama K, Kuriyama S, Akhter M, et al. Coffee consumption and mortality due to all causes, cardiovascular disease, and cancer in Japanese women. J Nutr. 2010;140:1007-1013.
11. Lopez-Garcia E, Van Dam RM, Li TY, et al. The relationship of coffee consumption with mortality. Ann Intern Med. 2008; 148:904-914.
12. Tamakoshi A, Lin Y, Kawado M, et al. Effect of coffee consumption on all-cause and total cancer mortality: findings from the JACC study. Eur J Epidemiol. 2011;26:285-293.
13. Andersen LF, Jacobs DR Jr, Carlsen MH, et al. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women's Health Study. Am J Clin Nutr. 2006;83:1039-1046.
14. La Vecchia CL. Coffee, liver enzymes, cirrhosis and liver cancer. J Hepatol. 2005;42:444-446.
15. Costentin CE, Roudot-Thoraval F, Zafrani ES, et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol. 2011;54:1123-1129.
16. Freedman ND, Everhart JE, Hoefs JC, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. J Hepatol. 2009;50:1360-1369.
17. Freedman ND, Curto TM, Lindsay KL, et al. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011;140:1961-1969.
18. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. J Hepatol. 2010;51:201-209.
19. Carrieri MP, Cohen J, Salmon-Ceron D, et al. Coffee consumption and reduced self-reported side effects in HIVHCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO13 HEPAVIH. J Hepatol. 2012;56:745-747.
20. Ong A, Wong VW, Wong GL, et al. The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. Liver Int. 2011;31:1047-1053.
21. Anty R, Marjoux S, Marinè-Barjoan E, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol. 2012;57:1090-1096.
22. Birerdinc A, Stepanova M, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;35:76-82.
23. Catalano D, Martines GF, Tonzuso A, et al. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2010;55:3200-3206.
24. Gutièrrez-Grobe Y, Chàvez-Tapia N, Sànchez-Valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol. 2012;11:350-355.
25. Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-436.
26. Corrao G, Lepore AR, Torchio P, et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. Eur J Epidemiol. 1994;10: 657-664.
27. Corrao G, Zambon A, Bagnardi V, et al. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol. 2001;11:458-465.
28. Gallus S, Tavani A, Negri E, et al. Does coffee protect against liver cirrhosis? Ann Epidemiol. 2002;12:202-205.
29. Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol. 2003;13:419-423.
30. Klatsky AL, Morton C, Udaltsova N, et al. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006;166:1190-1195.
31. La Vecchia C, Ferraroni M, Negri E, et al. Coffee consumption and digestive tract cancers. Cancer Res. 1989;49:1049-1051.
32. Ohishi W, Fujwara S, Cologne JB, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2008;17: 849-854.
33. Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. J Hepatol. 2008;48:129-136.
34. Leung WW, Ho SC, Chan HLY, et al. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol Community Health. 2011;65:556-558.
35. Arnesen E, Huseby NE, Brenn T, et al. The Tromso Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest. 1986;46:63-70.
36. Casiglia E, Spolaore P, Ginocchio G, et al. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol. 1993;9:293-297.
37. Honjo S, Kono S, Coleman MP, et al. Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol. 2001;54:823-829.
38. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2005;128:24-32.
39. Tanaka K, Tokunaga S, Kono S, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol. 1998;27:438-443.
40. Macaluso FS, Maida M, Minissale MG, et al. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 2013;2013:564645.
41. CarrieriMP, Lions C, Sogni P, et al. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol. 2014;60:46-53.
42. Cardin R, Piciocchi M, Martines D, et al. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 2013;45:499-504.
43. Vitaglione P, Morisco F, Mazzone G, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 2010;52:1652-1661.
44. Esposito F, Morisco F, Verde V, et al. Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. Aliment Pharmacol Ther. 2003;17: 595-601.
45. Salomone F, Li Volti G, Vitaglione P, et al. Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. Transl Res. 2013;13: 431-433.
46. Klatsky AL, Armstrong MA, Friedman GD. Coffee, tea, and mortality. Ann Epidemiol. 1993;3:375-381.
47. Ruhl CE, Everhart JE. Coffee and teas consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology. 2005;129:1928-1936.
48. Bravi F, Bosetti C, Tavani A, et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1413-1421.
49. Muriel P, Arauz J. Coffee and liver diseases. Fitoterapia. 2010;81:297-305.
50. Cavin C, Holzhaeuser D, Scharf G, et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol. 2002;40:1155-1163.
51. Huber WW, Rossmanith W, Grusch M, et al. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol. 2008;46:1230-1238.
52. Huber WW, Teitel CH, Coles BF, et al. Potential chemoprotective effects of the coffee components kahweol and cafestol palmitates via modification of hepatic N-acetyltransferase and glutathione S-transferase activities. Environ Mol Mutagen. 2004;44:265-276.
53. Lam LKT, Sparnins VL, Wattenberg LW. Isolation and identification of kahweol and cafestol palmitate as active constituents of green coffee beans that enhance glutathione S-transferase activity in the mouse. Cancer Res. 1982;42: 1193-1198.
54. Forrester LM, Neal GE, Judath DJ, et al. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc Natl Acad Sci U S A. 1990;87:8306-8310.